Literature DB >> 28877929

Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.

Anja Jäschke1, Boubacar Coulibaly2, Edmond J Remarque3, Hermann Bujard4, Christian Epp1.   

Abstract

Naturally acquired immunity against malaria is largely mediated by serum antibodies controlling levels of blood-stage parasites. A limited understanding of the antigenic targets and functional mechanisms of protective antibodies has hampered the development of efficient malaria vaccines. Besides directly inhibiting the growth of Plasmodium parasites, antibodies can opsonize merozoites and recruit immune effector cells such as monocytes and neutrophils. Antibodies against the vaccine candidate merozoite surface protein 1 (MSP-1) are acquired during natural infections and have been associated with protection against malaria in several epidemiological studies. Here we analyzed serum antibodies from semi-immune individuals from Burkina Faso for their potential (i) to directly inhibit the growth of P. falciparum blood stages in vitro and (ii) to opsonize merozoites and to induce the antibody-dependent respiratory burst (ADRB) activity of neutrophils. While a few sera that directly inhibited the growth of P. falciparum blood stages were identified, immunoglobulin G (IgG) from all individuals clearly mediated the activation of neutrophils. The level of neutrophil activation correlated with levels of antibodies to MSP-1, and affinity-purified MSP-1-specific antibodies elicited ADRB activity. Furthermore, immunization of nonhuman primates with recombinant full-size MSP-1 induced antibodies that efficiently opsonized P. falciparum merozoites. Reversing the function by preincubation with recombinant antigens allowed us to quantify the contribution of MSP-1 to the antiparasitic effect of serum antibodies. Our data suggest that MSP-1, especially the partially conserved subunit MSP-183, is a major target of opsonizing antibodies acquired during natural exposure to malaria. Induction of opsonizing antibodies might be a crucial effector mechanism for MSP-1-based malaria vaccines.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ADRB; P. falciparum MSP-1; neutrophil; opsonizing antibodies; respiratory burst

Mesh:

Substances:

Year:  2017        PMID: 28877929      PMCID: PMC5674199          DOI: 10.1128/CVI.00155-17

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  87 in total

1.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

2.  Mefloquine induces ROS mediated programmed cell death in malaria parasite: Plasmodium.

Authors:  Sarika Gunjan; Sunil Kumar Singh; Tanuj Sharma; Hemlata Dwivedi; Bhavana Singh Chauhan; Mohammad Imran Siddiqi; Renu Tripathi
Journal:  Apoptosis       Date:  2016-09       Impact factor: 4.677

3.  Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria.

Authors:  Linda Reiling; Jack S Richards; Freya J I Fowkes; Alyssa E Barry; Tony Triglia; Watcharee Chokejindachai; Pascal Michon; Livingstone Tavul; Peter M Siba; Alan F Cowman; Ivo Mueller; James G Beeson
Journal:  J Immunol       Date:  2010-10-20       Impact factor: 5.422

4.  Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion.

Authors:  Ute Woehlbier; Christian Epp; Fiona Hackett; Michael J Blackman; Hermann Bujard
Journal:  Malar J       Date:  2010-03-18       Impact factor: 2.979

5.  Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites.

Authors:  A A Holder; M J Lockyer; K G Odink; J S Sandhu; V Riveros-Moreno; S C Nicholls; Y Hillman; L S Davey; M L Tizard; R T Schwarz
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

6.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

7.  Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.

Authors:  Michelle J Boyle; Linda Reiling; Gaoqian Feng; Christine Langer; Faith H Osier; Harvey Aspeling-Jones; Yik Sheng Cheng; Janine Stubbs; Kevin K A Tetteh; David J Conway; James S McCarthy; Ivo Muller; Kevin Marsh; Robin F Anders; James G Beeson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

8.  Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.

Authors:  Faith Ha Osier; Gaoqian Feng; Michelle J Boyle; Christine Langer; Jingling Zhou; Jack S Richards; Fiona J McCallum; Linda Reiling; Anthony Jaworowski; Robin F Anders; Kevin Marsh; James G Beeson
Journal:  BMC Med       Date:  2014-07-01       Impact factor: 8.775

9.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.

Authors:  Linda M Murungi; Gathoni Kamuyu; Brett Lowe; Philip Bejon; Michael Theisen; Samson M Kinyanjui; Kevin Marsh; Faith H A Osier
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

View more
  10 in total

Review 1.  Novel Strategies for Malaria Vaccine Design.

Authors:  Augustina Frimpong; Kwadwo Asamoah Kusi; Michael Fokuo Ofori; Wilfred Ndifon
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

Review 2.  The Rough Guide to Monocytes in Malaria Infection.

Authors:  Amaya Ortega-Pajares; Stephen J Rogerson
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

3.  Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.

Authors:  Rafiou Adamou; Célia Dechavanne; Ibrahim Sadissou; Tania d'Almeida; Aziz Bouraima; Paulin Sonon; Roukiyath Amoussa; Gilles Cottrell; Agnès Le Port; Michael Theisen; Edmond J Remarque; Shirley Longacre; Kabirou Moutairou; Achille Massougbodji; Adrian J F Luty; Gregory Nuel; Florence Migot-Nabias; Ambaliou Sanni; André Garcia; Jacqueline Milet; David Courtin
Journal:  Malar J       Date:  2019-06-11       Impact factor: 2.979

4.  Computational and experimental analysis of the glycophosphatidylinositol-anchored proteome of the human parasitic nematode Brugia malayi.

Authors:  Fana B Mersha; Leslie K Cortes; Ashley N Luck; Colleen M McClung; Cristian I Ruse; Christopher H Taron; Jeremy M Foster
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

Review 5.  Neutrophils and Malaria.

Authors:  Elizabeth H Aitken; Agersew Alemu; Stephen J Rogerson
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

6.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

Review 7.  Targeting the Plasmodium falciparum proteome and organelles for potential antimalarial drug candidates.

Authors:  James Abugri; Joseph Ayariga; Samuel Sunyazi Sunwiale; Cletus Adiyaga Wezena; Julien Agyemang Gyamfi; Michael Adu-Frimpong; Godfred Agongo; Julius Tieroyaare Dongdem; Daniel Abugri; Bismarck Dinko
Journal:  Heliyon       Date:  2022-08-24

Review 8.  [Development of malaria vaccines-state of the art].

Authors:  Wolfram Gottfried Metzger; Zita Sulyok; Antje Theurer; Carsten Köhler
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-01       Impact factor: 1.513

Review 9.  Naturally Acquired Humoral Immunity Against Plasmodium falciparum Malaria.

Authors:  S Jake Gonzales; Raphael A Reyes; Ashley E Braddom; Gayani Batugedara; Sebastiaan Bol; Evelien M Bunnik
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

10.  A comprehensive study of epitopes and immune reactivity among Plasmodium species.

Authors:  Meenu Kalkal; Amit Kalkal; Sandeep Kumar Dhanda; Emily Das; Veena Pande; Jyoti Das
Journal:  BMC Microbiol       Date:  2022-03-11       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.